How have LXRX and SANA total returns compared?

Over the past 5 years, LXRX delivered -18.54% and SANA delivered -32.33% annualized total return. Past performance doesn't predict future results.

Lexicon Pharmaceuticals, Inc. (LXRX) vs Sana Biotechnology, Inc. (SANA)

A side-by-side comparison of Lexicon Pharmaceuticals, Inc. and Sana Biotechnology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

LXRX

Lexicon Pharmaceuticals, Inc.

$773M

$1.74HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT

SANA

Sana Biotechnology, Inc.

$778M

$2.80HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT

Total return — LXRX vs SANA

growth of $100 · dividends reinvested · last 6y

LXRX -79.0% (-22.9%/yr)SANA -91.8% (-34.1%/yr)LXRX compounded faster over this window

LXRX SANA

LXRX vs SANA: by the numbers

•SANA is the larger company ($778M vs $773M market cap).
•Both run net losses; SANA's is the smaller (0.00% vs -147.38% net margin).

Metrics side by side

Valuation

Metric	LXRX	SANA
P/S ratio	18.64	N/A
P/B ratio	4.43	5.03

Profitability

Metric	LXRX	SANA
Gross margin	98.85%	0.00%
Operating margin	-98.21%	0.00%
Net margin	-147.38%	0.00%
ROE	-35.02%	-137.04%
ROIC	-23.16%	-67.58%

Growth (annualized)

Metric	LXRX	SANA
Revenue CAGR (5Y)	42.36%	N/A
Total return CAGR (5Y)	-18.54%	-32.33%

Frequently asked

How have LXRX and SANA total returns compared?: Over the past 5 years, LXRX delivered -18.54% and SANA delivered -32.33% annualized total return. Past performance doesn't predict future results.

Go deeper

Full LXRX analysis Full SANA analysis Interactive comparison tool

Dig into the metrics

Lexicon Pharmaceuticals ROE Sana Biotechnology ROE Lexicon Pharmaceuticals operating margin Sana Biotechnology operating margin Lexicon Pharmaceuticals revenue growth Sana Biotechnology revenue growth Lexicon Pharmaceuticals free cash flow Sana Biotechnology free cash flow

Lexicon Pharmaceuticals & Sana Biotechnology appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.